Spine Biologics Market – Global Industry Analysis and Forecast (2023-2029) – By Product, Surgery Type, End User and Region


Spine Biologics Market size is expected to grow at a CAGR of 4.3% during the forecast period and the market size is expected to reach nearly USD 3.50 Bn by 2029.

The report includes the analysis of impact of COVID-19 lock-down on the revenue of market leaders, followers, and disrupters. Since lock down was implemented differently in different regions and countries, impact of same is also different by regions and segments. The report has covered the current short term and long term impact on the market, same will help decision makers to prepare the outline for short term and long term strategies for companies by region. Spine Biologics MarketTo know about the Research Methodology:-Request Free Sample Report

Spine biologics is a treatment that is used during spine fusion surgery for the treatment of spinal deformities that comprise spinal cord injuries, trauma, degenerative disc disease, and tumors. It stimulates the growth of the bone formation over different stages which include inflammatory, repair, and remodeling.

Major factors that are driving the spine biologics market growth include an increase in the number of geriatric population, benefits providing by spine biologics is faster recovery, minimal postoperative time, and ability to activate cellular growth. Spinal injuries can be because of the enlargement of bones & joints, thickening of the band of the tissue, which supports the spine. This is the key factor that is fuelling market growth in the upcoming years. People who are at the high risk of spinal deformities need to undergo spinal fusion surgery thus growing its demand in the global market. However, higher cost of the bone grafts, hostile reimbursement scenario, and concerns regarding the bone grafting procedures are expected to hinder the spine biologics market growth.

The report covers in-depth analysis of driving factors, opportunities, restraints, and challenges for gaining the key insight of the market. The report emphasizes on all the key trends that play a significant role in the enlargement of the market from 2022 to 2029.

Based on the product, the spinal allografts segment is expected to register a major XX% revenue share in the spine biologics market globally. The spinal allografts are an assumption of allografts over auto grafts is quickly increasing owing to properties such as immediate operational support and osteoconductivity. Moreover, allografts form not require another surgery to harvest the bone, and coiled healing. Hence, natural bone grafts are harvested from a patient’s body.

The hospital's segment is expected to dominate the xx% market share during the forecast period. The hospitals' segment is mainly determined by an improved number of spine fusion surgeries performed in these facilities. However, high hospitalization charges have converted into reducing patient admittances in hospitals, with the number of outpatient visits observing a surge. This is likely to threaten the implementation of spine biologics in hospital surroundings over the forecast period.

Region-wise, The Asia Pacific market is projected to demonstrate significant growth owing to the presence of a large patient pool and developing awareness among surgeons and patients pertinent to the benefits of biologics. Improvements in infrastructure and healthcare facilities in the region and the high prevalence of spine injuries are some of the factors dynamic the regional market. Changing lifestyle designs have resulted in an increasing prevalence of obesity, which is also likely to fuel the market over the forecast period.

The report covers the recent development in the spine biologics market like, in March 2021, Cell Right Technologies Signed a Multi-Year Distribution Agreement By Arthrex Inc, a producer of orthopedic surgical solutions. Cell right is an establishment that creations osteobiologics which are used in orthopedic, spine and intensifying the healing ventures of problems caused by pain & disease. The multi-time commitment would provide surgeons arrival to qualified osteobiologics and advanced surgical instrumentation and techniques helping to succeed better patient effects.

The objective of the report is to present a complete calculation of the Global Spine Biologics Market and contains thoughtful insights, historical data, facts, industry-validated market data and plans with a suitable set of assumptions and methodology. The report also helps in the Global Spine Biologics Market is a dynamic structure by identifying and analyzing the market segments and project the global market size. The additional, report also focuses on the competitive analysis of key player’s by-product, financial position, price, product portfolio, growth strategies, and regional presence. The report also provides PEST analysis, PORTER’s analysis, and SWOT analysis to address the question of shareholders to prioritizing the efforts and investment shortly to the emerging segment in the Global Spine Biologics Market.

 Spine Biologics Market Scope: Inquire before buying






Spine Biologics Market




Report Coverage
Details




Base Year:
2022
Forecast Period:
2023-2029




Historical Data:
2018 to 2022
Market Size in 2022:
US $ 2.61 Bn.




Forecast Period 2023 to 2029 CAGR:
4.3%
Market Size in 2029:
US $ 3.50 Bn.




 Segments Covered:
by Product
Bone Allografts
Machined bone allograft
Demineralized bone matrix
Bone Graft Substitute
Synthetic Bone Grafts
Demineralized Bone Matrix (DBM)
Bone Morphogenetic Proteins (BMP)
Spinal Allografts
Machined Bones Allograft
Demineralized Bone Matrix
Platelet Rich Plasma
Cell-based Matrix




by Surgery Type
Anterior Cervical Discectomy and Fusion (ACDF)
Transforamenal Lumbar Interbody Fusion (TLIF)
Anterior Lumbar Interbody Fusion (ALIF)
Lateral Lumbar Interbody Fusion (LLIF)
Others




by End-User
Hospitals
Ambulatory Surgical Centers
Others






Spine Biologics Market By Region

North America (United States, Canada and Mexico)
Europe (UK, France, Germany, Italy, Spain, Sweden, Austria and Rest of Europe)
Asia Pacific (China, South Korea, Japan, India, Australia, Indonesia, Malaysia, Vietnam, Taiwan, Bangladesh, Pakistan and Rest of APAC)
Middle East and Africa (South Africa, GCC, Egypt, Nigeria and Rest of ME&A)
South America (Brazil, Argentina Rest of South America)

 Spine Biologics Market Key Players

1. Medtronic Inc.
2. DePuy Synthes Companies
3. Zimmer Holding Inc.
4. Nuvasive Inc
5. Stryker Corporation
6. Orthofix International N.V.
7. Exactech Inc.
8. Wright Medical Technology
9. Alphatec Holdings
10.SeaSpine
11.Globus Medical
12.RTI Surgical

Frequently Asked Questions:

1. Which region has the largest share in Global Spine Biologics Market?
Ans: Asia Pacific region held the highest share in 2022.

2. What is the growth rate of Global Spine Biologics Market?
Ans: The Global Spine Biologics Market is growing at a CAGR of 4.3% during forecasting period 2023-2029.

3. What is scope of the Global Spine Biologics market report?
Ans: Global Spine Biologics Market report helps with the PESTEL, PORTER, COVID-19 Impact analysis, Recommendations for Investors & Leaders, and market estimation of the forecast period.

4. Who are the key players in Global Spine Biologics market?
Ans: The important key players in the Global Spine Biologics Market are – Medtronic Inc., DePuy Synthes Companies, Zimmer Holding Inc., Nuvasive Inc, Stryker Corporation, Orthofix International N.V., Exactech Inc., Wright Medical Technology, Alphatec Holdings, SeaSpine, Globus Medical, and RTI Surgical

5. What is the study period of this market?
Ans: The Global Spine Biologics Market is studied from 2022 to 2029. 





Spine Biologics Market

1. Preface
1.1. Report Scope and Market Segmentation
1.2. Research Highlights
1.3. Research Objectives

2. Assumptions and Research Methodology
2.1. Report Assumptions
2.2. Abbreviations
2.3. Research Methodology
2.3.1. Secondary Research
2.3.1.1. Secondary data
2.3.1.2. Secondary Sources
2.3.2. Primary Research
2.3.2.1. Data from Primary Sources
2.3.2.2. Breakdown of Primary Sources

3. Executive Summary: Spine Biologics Market Size, by Market Value (US$ Bn)

4. Market Overview
4.1. Introduction
4.2. Market Indicator
4.2.1. Drivers
4.2.2. Restraints
4.2.3. Opportunities
4.2.4. Challenges
4.3. Porter’s Analysis
4.4. Value Chain Analysis
4.5. Market Risk Analysis
4.6. SWOT Analysis
4.7. Industry Trends and Emerging Technologies

5. Supply Side and Demand Side Indicators

6. Spine Biologics Market Analysis and Forecast
6.1. Spine Biologics Market Size & Y-o-Y Growth Analysis
6.1.1. North America
6.1.2. Europe
6.1.3. Asia Pacific
6.1.4. Middle East & Africa
6.1.5. South America

7. Spine Biologics Market Analysis and Forecast, by Product
7.1. Introduction and Definition
7.2. Key Findings
7.3. Spine Biologics Market Value Share Analysis, by Product
7.4. Spine Biologics Market Size (US$ Bn) Forecast, by Product
7.5. Spine Biologics Market Analysis, by Product
7.6. Spine Biologics Market Attractiveness Analysis, by Product

8. Spine Biologics Market Analysis and Forecast, by Surgery Type
8.1. Introduction and Definition
8.2. Key Findings
8.3. Spine Biologics Market Value Share Analysis, by Surgery Type
8.4. Spine Biologics Market Size (US$ Bn) Forecast, by Surgery Type
8.5. Spine Biologics Market Analysis, by Surgery Type
8.6. Spine Biologics Market Attractiveness Analysis, by Surgery Type

9. Spine Biologics Market Analysis and Forecast, by End-User
9.1. Introduction and Definition
9.2. Key Findings
9.3. Spine Biologics Market Value Share Analysis, by End-User
9.4. Spine Biologics Market Size (US$ Bn) Forecast, by End-User
9.5. Spine Biologics Market Analysis, by End-User
9.6. Spine Biologics Market Attractiveness Analysis, by End-User

10. Spine Biologics Market Analysis, by Region
10.1. Spine Biologics Market Value Share Analysis, by Region
10.2. Spine Biologics Market Size (US$ Bn) Forecast, by Region
10.3. Spine Biologics Market Attractiveness Analysis, by Region

11. North America Spine Biologics Market Analysis
11.1. Key Findings
11.2. North America Spine Biologics Market Overview
11.3. North America Spine Biologics Market Value Share Analysis, by Product
11.4. North America Spine Biologics Market Forecast, by Product
11.4.1. Bone Allografts
11.4.1.1. Machined bone allograft
11.4.1.2. Demineralized bone matrix
11.4.2. Bone Graft Substitute
11.4.2.1. Synthetic Bone Grafts
11.4.2.2. Demineralized Bone Matrix (DBM)
11.4.2.3. Bone Morphogenetic Proteins (BMP)
11.4.3. Spinal Allografts
11.4.3.1. Machined Bones Allograft
11.4.3.2. Demineralized Bone Matrix
11.4.4. Platelet Rich Plasma
11.4.5. Cell-based Matrix
11.5. North America Spine Biologics Market Value Share Analysis, by Surgery Type
11.6. North America Spine Biologics Market Forecast, by Surgery Type
11.6.1. Anterior Cervical Discectomy and Fusion (ACDF)
11.6.2. Transforamenal Lumbar Interbody Fusion (TLIF)
11.6.3. Anterior Lumbar Interbody Fusion (ALIF)
11.6.4. Lateral Lumbar Interbody Fusion (LLIF)
11.6.5. Others
11.7. North America Spine Biologics Market Value Share Analysis, by End-User
11.8. North America Spine Biologics Market Forecast, by End-User
11.8.1. Hospitals
11.8.2. Ambulatory Surgical Centers
11.8.3. Others
11.9. North America Spine Biologics Market Value Share Analysis, by Country
11.10. North America Spine Biologics Market Forecast, by Country
11.10.1. U.S.
11.10.2. Canada
11.11. North America Spine Biologics Market Analysis, by Country
11.12. U.S. Spine Biologics Market Forecast, by Product
11.12.1. Bone Allografts
11.12.1.1. Machined bone allograft
11.12.1.2. Demineralized bone matrix
11.12.2. Bone Graft Substitute
11.12.2.1. Synthetic Bone Grafts
11.12.2.2. Demineralized Bone Matrix (DBM)
11.12.2.3. Bone Morphogenetic Proteins (BMP)
11.12.3. Spinal Allografts
11.12.3.1. Machined Bones Allograft
11.12.3.2. Demineralized Bone Matrix
11.12.4. Platelet Rich Plasma
11.12.5. Cell-based Matrix
11.13. U.S. Spine Biologics Market Forecast, by Surgery Type
11.13.1. Anterior Cervical Discectomy and Fusion (ACDF)
11.13.2. Transforamenal Lumbar Interbody Fusion (TLIF)
11.13.3. Anterior Lumbar Interbody Fusion (ALIF)
11.13.4. Lateral Lumbar Interbody Fusion (LLIF)
11.13.5. Others
11.14. U.S. Spine Biologics Market Forecast, by End-User
11.14.1. Hospitals
11.14.2. Ambulatory Surgical Centers
11.14.3. Others
11.15. Canada Spine Biologics Market Forecast, by Product
11.15.1. Bone Allografts
11.15.1.1. Machined bone allograft
11.15.1.2. Demineralized bone matrix
11.15.2. Bone Graft Substitute
11.15.2.1. Synthetic Bone Grafts
11.15.2.2. Demineralized Bone Matrix (DBM)
11.15.2.3. Bone Morphogenetic Proteins (BMP)
11.15.3. Spinal Allografts
11.15.3.1. Machined Bones Allograft
11.15.3.2. Demineralized Bone Matrix
11.15.4. Platelet Rich Plasma
11.15.5. Cell-based Matrix
11.16. Steel Canada Spine Biologics Market Forecast, by Surgery Type
11.16.1. Anterior Cervical Discectomy and Fusion (ACDF)
11.16.2. Transforamenal Lumbar Interbody Fusion (TLIF)
11.16.3. Anterior Lumbar Interbody Fusion (ALIF)
11.16.4. Lateral Lumbar Interbody Fusion (LLIF)
11.16.5. Others
11.17. Canada Spine Biologics Market Forecast, by End-User
11.17.1. Hospitals
11.17.2. Ambulatory Surgical Centers
11.17.3. Others
11.18. North America Spine Biologics Market Attractiveness Analysis
11.18.1. By Product
11.18.2. By Surgery Type
11.18.3. By End-User
11.19. PEST Analysis
11.20. Key Trends
11.21. Key Developments

12. Europe Spine Biologics Market Analysis
12.1. Key Findings
12.2. Europe Spine Biologics Market Overview
12.3. Europe Spine Biologics Market Value Share Analysis, by Product
12.4. Europe Spine Biologics Market Forecast, by Product
12.4.1. Bone Allografts
12.4.1.1. Machined bone allograft
12.4.1.2. Demineralized bone matrix
12.4.2. Bone Graft Substitute
12.4.2.1. Synthetic Bone Grafts
12.4.2.2. Demineralized Bone Matrix (DBM)
12.4.2.3. Bone Morphogenetic Proteins (BMP)
12.4.3. Spinal Allografts
12.4.3.1. Machined Bones Allograft
12.4.3.2. Demineralized Bone Matrix
12.4.4. Platelet Rich Plasma
12.4.5. Cell-based Matrix
12.5. Europe Spine Biologics Market Value Share Analysis, by Surgery Type
12.6. Europe Spine Biologics Market Forecast, by Surgery Type
12.6.1. Anterior Cervical Discectomy and Fusion (ACDF)
12.6.2. Transforamenal Lumbar Interbody Fusion (TLIF)
12.6.3. Anterior Lumbar Interbody Fusion (ALIF)
12.6.4. Lateral Lumbar Interbody Fusion (LLIF)
12.6.5. Others
12.7. Europe Spine Biologics Market Value Share Analysis, by End-User
12.8. Europe Spine Biologics Market Forecast, by End-User
12.8.1. Hospitals
12.8.2. Ambulatory Surgical Centers
12.8.3. Others
12.9. Europe Spine Biologics Market Value Share Analysis, by Country
12.10. Europe Spine Biologics Market Forecast, by Country
12.10.1. Germany
12.10.2. U.K.
12.10.3. France
12.10.4. Italy
12.10.5. Spain
12.10.6. Rest of Europe
12.11. Europe Spine Biologics Market Analysis, by Country
12.12. Germany Spine Biologics Market Forecast, by Product
12.12.1. Bone Allografts
12.12.1.1. Machined bone allograft
12.12.1.2. Demineralized bone matrix
12.12.2. Bone Graft Substitute
12.12.2.1. Synthetic Bone Grafts
12.12.2.2. Demineralized Bone Matrix (DBM)
12.12.2.3. Bone Morphogenetic Proteins (BMP)
12.12.3. Spinal Allografts
12.12.3.1. Machined Bones Allograft
12.12.3.2. Demineralized Bone Matrix
12.12.4. Platelet Rich Plasma
12.12.5. Cell-based Matrix
12.13. Germany Spine Biologics Market Forecast, by Surgery Type
12.13.1. Anterior Cervical Discectomy and Fusion (ACDF)
12.13.2. Transforamenal Lumbar Interbody Fusion (TLIF)
12.13.3. Anterior Lumbar Interbody Fusion (ALIF)
12.13.4. Lateral Lumbar Interbody Fusion (LLIF)
12.13.5. Others
12.14. Germany Spine Biologics Market Forecast, by End-User
12.14.1. Hospitals
12.14.2. Ambulatory Surgical Centers
12.14.3. Others
12.15. U.K. Spine Biologics Market Forecast, by Product
12.15.1. Bone Allografts
12.15.1.1. Machined bone allograft
12.15.1.2. Demineralized bone matrix
12.15.2. Bone Graft Substitute
12.15.2.1. Synthetic Bone Grafts
12.15.2.2. Demineralized Bone Matrix (DBM)
12.15.2.3. Bone Morphogenetic Proteins (BMP)
12.15.3. Spinal Allografts
12.15.3.1. Machined Bones Allograft
12.15.3.2. Demineralized Bone Matrix
12.15.4. Platelet Rich Plasma
12.15.5. Cell-based Matrix
12.16. U.K. Spine Biologics Market Forecast, by Surgery Type
12.16.1. Anterior Cervical Discectomy and Fusion (ACDF)
12.16.2. Transforamenal Lumbar Interbody Fusion (TLIF)
12.16.3. Anterior Lumbar Interbody Fusion (ALIF)
12.16.4. Lateral Lumbar Interbody Fusion (LLIF)
12.16.5. Others
12.17. U.K. Spine Biologics Market Forecast, by End-User
12.17.1. Hospitals
12.17.2. Ambulatory Surgical Centers
12.17.3. Others
12.18. France Spine Biologics Market Forecast, by Product
12.18.1. Bone Allografts
12.18.1.1. Machined bone allograft
12.18.1.2. Demineralized bone matrix
12.18.2. Bone Graft Substitute
12.18.2.1. Synthetic Bone Grafts
12.18.2.2. Demineralized Bone Matrix (DBM)
12.18.2.3. Bone Morphogenetic Proteins (BMP)
12.18.3. Spinal Allografts
12.18.3.1. Machined Bones Allograft
12.18.3.2. Demineralized Bone Matrix
12.18.4. Platelet Rich Plasma
12.18.5. Cell-based Matrix
12.19. France Spine Biologics Market Forecast, by Surgery Type
12.19.1. Anterior Cervical Discectomy and Fusion (ACDF)
12.19.2. Transforamenal Lumbar Interbody Fusion (TLIF)
12.19.3. Anterior Lumbar Interbody Fusion (ALIF)
12.19.4. Lateral Lumbar Interbody Fusion (LLIF)
12.19.5. Others
12.20. France Spine Biologics Market Forecast, by End-User
12.20.1. Hospitals
12.20.2. Ambulatory Surgical Centers
12.20.3. Others
12.21. Italy Spine Biologics Market Forecast, by Product
12.21.1. Bone Allografts
12.21.1.1. Machined bone allograft
12.21.1.2. Demineralized bone matrix
12.21.2. Bone Graft Substitute
12.21.2.1. Synthetic Bone Grafts
12.21.2.2. Demineralized Bone Matrix (DBM)
12.21.2.3. Bone Morphogenetic Proteins (BMP)
12.21.3. Spinal Allografts
12.21.3.1. Machined Bones Allograft
12.21.3.2. Demineralized Bone Matrix
12.21.4. Platelet Rich Plasma
12.21.5. Cell-based Matrix
12.22. Italy Spine Biologics Market Forecast, by Surgery Type
12.22.1. Anterior Cervical Discectomy and Fusion (ACDF)
12.22.2. Transforamenal Lumbar Interbody Fusion (TLIF)
12.22.3. Anterior Lumbar Interbody Fusion (ALIF)
12.22.4. Lateral Lumbar Interbody Fusion (LLIF)
12.22.5. Others
12.23. Italy Spine Biologics Market Forecast, by End-User
12.23.1. Hospitals
12.23.2. Ambulatory Surgical Centers
12.23.3. Others
12.24. Spain Spine Biologics Market Forecast, by Product
12.24.1. Bone Allografts
12.24.1.1. Machined bone allograft
12.24.1.2. Demineralized bone matrix
12.24.2. Bone Graft Substitute
12.24.2.1. Synthetic Bone Grafts
12.24.2.2. Demineralized Bone Matrix (DBM)
12.24.2.3. Bone Morphogenetic Proteins (BMP)
12.24.3. Spinal Allografts
12.24.3.1. Machined Bones Allograft
12.24.3.2. Demineralized Bone Matrix
12.24.4. Platelet Rich Plasma
12.24.5. Cell-based Matrix
12.25. Spain Spine Biologics Market Forecast, by Surgery Type
12.25.1. Anterior Cervical Discectomy and Fusion (ACDF)
12.25.2. Transforamenal Lumbar Interbody Fusion (TLIF)
12.25.3. Anterior Lumbar Interbody Fusion (ALIF)
12.25.4. Lateral Lumbar Interbody Fusion (LLIF)
12.25.5. Others
12.26. Spain Spine Biologics Market Forecast, by End-User
12.26.1. Hospitals
12.26.2. Ambulatory Surgical Centers
12.26.3. Others
12.27. Rest of Europe Spine Biologics Market Forecast, by Product
12.27.1. Bone Allografts
12.27.1.1. Machined bone allograft
12.27.1.2. Demineralized bone matrix
12.27.2. Bone Graft Substitute
12.27.2.1. Synthetic Bone Grafts
12.27.2.2. Demineralized Bone Matrix (DBM)
12.27.2.3. Bone Morphogenetic Proteins (BMP)
12.27.3. Spinal Allografts
12.27.3.1. Machined Bones Allograft
12.27.3.2. Demineralized Bone Matrix
12.27.4. Platelet Rich Plasma
12.27.5. Cell-based Matrix
12.28. Rest of Europe Spine Biologics Market Forecast, by Surgery Type
12.28.1. Anterior Cervical Discectomy and Fusion (ACDF)
12.28.2. Transforamenal Lumbar Interbody Fusion (TLIF)
12.28.3. Anterior Lumbar Interbody Fusion (ALIF)
12.28.4. Lateral Lumbar Interbody Fusion (LLIF)
12.28.5. Others
12.29. Rest Of Europe Spine Biologics Market Forecast, by End-User
12.29.1. Hospitals
12.29.2. Ambulatory Surgical Centers
12.29.3. Others
12.30. Europe Spine Biologics Market Attractiveness Analysis
12.30.1. By Product
12.30.2. By Surgery Type
12.30.3. By End-User
12.31. PEST Analysis
12.32. Key Trends
12.33. Key Developments

13. Asia Pacific Spine Biologics Market Analysis
13.1. Key Findings
13.2. Asia Pacific Spine Biologics Market Overview
13.3. Asia Pacific Spine Biologics Market Value Share Analysis, by Product
13.4. Asia Pacific Spine Biologics Market Forecast, by Product
13.4.1. Bone Allografts
13.4.1.1. Machined bone allograft
13.4.1.2. Demineralized bone matrix
13.4.2. Bone Graft Substitute
13.4.2.1. Synthetic Bone Grafts
13.4.2.2. Demineralized Bone Matrix (DBM)
13.4.2.3. Bone Morphogenetic Proteins (BMP)
13.4.3. Spinal Allografts
13.4.3.1. Machined Bones Allograft
13.4.3.2. Demineralized Bone Matrix
13.4.4. Platelet Rich Plasma
13.4.5. Cell-based Matrix
13.5. Asia Pacific Spine Biologics Market Value Share Analysis, by Surgery Type
13.6. Asia Pacific Spine Biologics Market Forecast, by Surgery Type
13.6.1. Anterior Cervical Discectomy and Fusion (ACDF)
13.6.2. Transforamenal Lumbar Interbody Fusion (TLIF)
13.6.3. Anterior Lumbar Interbody Fusion (ALIF)
13.6.4. Lateral Lumbar Interbody Fusion (LLIF)
13.6.5. Others
13.7. Asia Pacific Spine Biologics Market Value Share Analysis, by End-User
13.8. Asia Pacific Spine Biologics Market Forecast, by End-User
13.8.1. Hospitals
13.8.2. Ambulatory Surgical Centers
13.8.3. Others
13.9. Asia Pacific Spine Biologics Market Value Share Analysis, by Country
13.10. Asia Pacific Spine Biologics Market Forecast, by Country
13.10.1. China
13.10.2. India
13.10.3. Japan
13.10.4. ASEAN
13.10.5. Rest of Asia Pacific
13.11. Asia Pacific Spine Biologics Market Analysis, by Country
13.12. China Spine Biologics Market Forecast, by Product
13.12.1. Bone Allografts
13.12.1.1. Machined bone allograft
13.12.1.2. Demineralized bone matrix
13.12.2. Bone Graft Substitute
13.12.2.1. Synthetic Bone Grafts
13.12.2.2. Demineralized Bone Matrix (DBM)
13.12.2.3. Bone Morphogenetic Proteins (BMP)
13.12.3. Spinal Allografts
13.12.3.1. Machined Bones Allograft
13.12.3.2. Demineralized Bone Matrix
13.12.4. Platelet Rich Plasma
13.12.5. Cell-based Matrix
13.13. China Spine Biologics Market Forecast, by Surgery Type
13.13.1. Anterior Cervical Discectomy and Fusion (ACDF)
13.13.2. Transforamenal Lumbar Interbody Fusion (TLIF)
13.13.3. Anterior Lumbar Interbody Fusion (ALIF)
13.13.4. Lateral Lumbar Interbody Fusion (LLIF)
13.13.5. Others
13.14. China Spine Biologics Market Forecast, by End-User
13.14.1. Hospitals
13.14.2. Ambulatory Surgical Centers
13.14.3. Others
13.15. India Spine Biologics Market Forecast, by Product
13.15.1. Bone Allografts
13.15.1.1. Machined bone allograft
13.15.1.2. Demineralized bone matrix
13.15.2. Bone Graft Substitute
13.15.2.1. Synthetic Bone Grafts
13.15.2.2. Demineralized Bone Matrix (DBM)
13.15.2.3. Bone Morphogenetic Proteins (BMP)
13.15.3. Spinal Allografts
13.15.3.1. Machined Bones Allograft
13.15.3.2. Demineralized Bone Matrix
13.15.4. Platelet Rich Plasma
13.15.5. Cell-based Matrix
13.16. India Spine Biologics Market Forecast, by Surgery Type
13.16.1. Anterior Cervical Discectomy and Fusion (ACDF)
13.16.2. Transforamenal Lumbar Interbody Fusion (TLIF)
13.16.3. Anterior Lumbar Interbody Fusion (ALIF)
13.16.4. Lateral Lumbar Interbody Fusion (LLIF)
13.16.5. Others
13.17. India Spine Biologics Market Forecast, by End-User
13.17.1. Hospitals
13.17.2. Ambulatory Surgical Centers
13.17.3. Others
13.18. Japan Spine Biologics Market Forecast, by Product
13.18.1. Bone Allografts
13.18.1.1. Machined bone allograft
13.18.1.2. Demineralized bone matrix
13.18.2. Bone Graft Substitute
13.18.2.1. Synthetic Bone Grafts
13.18.2.2. Demineralized Bone Matrix (DBM)
13.18.2.3. Bone Morphogenetic Proteins (BMP)
13.18.3. Spinal Allografts
13.18.3.1. Machined Bones Allograft
13.18.3.2. Demineralized Bone Matrix
13.18.4. Platelet Rich Plasma
13.18.5. Cell-based Matrix
13.19. Japan Spine Biologics Market Forecast, by Surgery Type
13.19.1. Anterior Cervical Discectomy and Fusion (ACDF)
13.19.2. Transforamenal Lumbar Interbody Fusion (TLIF)
13.19.3. Anterior Lumbar Interbody Fusion (ALIF)
13.19.4. Lateral Lumbar Interbody Fusion (LLIF)
13.19.5. Others
13.20. Japan Spine Biologics Market Forecast, by End-User
13.20.1. Hospitals
13.20.2. Ambulatory Surgical Centers
13.20.3. Others
13.21. ASEAN Spine Biologics Market Forecast, by Product
13.21.1. Bone Allografts
13.21.1.1. Machined bone allograft
13.21.1.2. Demineralized bone matrix
13.21.2. Bone Graft Substitute
13.21.2.1. Synthetic Bone Grafts
13.21.2.2. Demineralized Bone Matrix (DBM)
13.21.2.3. Bone Morphogenetic Proteins (BMP)
13.21.3. Spinal Allografts
13.21.3.1. Machined Bones Allograft
13.21.3.2. Demineralized Bone Matrix
13.21.4. Platelet Rich Plasma
13.21.5. Cell-based Matrix
13.22. ASEAN Spine Biologics Market Forecast, by Surgery Type
13.22.1. Anterior Cervical Discectomy and Fusion (ACDF)
13.22.2. Transforamenal Lumbar Interbody Fusion (TLIF)
13.22.3. Anterior Lumbar Interbody Fusion (ALIF)
13.22.4. Lateral Lumbar Interbody Fusion (LLIF)
13.22.5. Others
13.23. ASEAN Spine Biologics Market Forecast, by End-User
13.23.1. Hospitals
13.23.2. Ambulatory Surgical Centers
13.23.3. Others
13.24. Rest of Asia Pacific Spine Biologics Market Forecast, by Product
13.24.1. Bone Allografts
13.24.1.1. Machined bone allograft
13.24.1.2. Demineralized bone matrix
13.24.2. Bone Graft Substitute
13.24.2.1. Synthetic Bone Grafts
13.24.2.2. Demineralized Bone Matrix (DBM)
13.24.2.3. Bone Morphogenetic Proteins (BMP)
13.24.3. Spinal Allografts
13.24.3.1. Machined Bones Allograft
13.24.3.2. Demineralized Bone Matrix
13.24.4. Platelet Rich Plasma
13.24.5. Cell-based Matrix
13.25. Rest of Asia Pacific Spine Biologics Market Forecast, by Surgery Type
13.25.1. Anterior Cervical Discectomy and Fusion (ACDF)
13.25.2. Transforamenal Lumbar Interbody Fusion (TLIF)
13.25.3. Anterior Lumbar Interbody Fusion (ALIF)
13.25.4. Lateral Lumbar Interbody Fusion (LLIF)
13.25.5. Others
13.26. Rest of Asia Pacific Spine Biologics Market Forecast, by End-User
13.26.1. Hospitals
13.26.2. Ambulatory Surgical Centers
13.26.3. Others
13.27. Asia Pacific Spine Biologics Market Attractiveness Analysis
13.27.1. By Product
13.27.2. By Surgery Type
13.27.3. By End-User
13.28. PEST Analysis
13.29. Key Trends
13.30. Key Developments

14. Middle East & Africa Spine Biologics Market Analysis
14.1. Key Findings
14.2. Middle East & Africa Spine Biologics Market Overview
14.3. Middle East & Africa Spine Biologics Market Value Share Analysis, by Product
14.4. Middle East & Africa Spine Biologics Market Forecast, by Product
14.4.1. Bone Allografts
14.4.1.1. Machined bone allograft
14.4.1.2. Demineralized bone matrix
14.4.2. Bone Graft Substitute
14.4.2.1. Synthetic Bone Grafts
14.4.2.2. Demineralized Bone Matrix (DBM)
14.4.2.3. Bone Morphogenetic Proteins (BMP)
14.4.3. Spinal Allografts
14.4.3.1. Machined Bones Allograft
14.4.3.2. Demineralized Bone Matrix
14.4.4. Platelet Rich Plasma
14.4.5. Cell-based Matrix
14.5. Middle East & Africa Spine Biologics Market Value Share Analysis, by Surgery Type
14.6. Middle East & Africa Spine Biologics Market Forecast, by Surgery Type
14.6.1. Anterior Cervical Discectomy and Fusion (ACDF)
14.6.2. Transforamenal Lumbar Interbody Fusion (TLIF)
14.6.3. Anterior Lumbar Interbody Fusion (ALIF)
14.6.4. Lateral Lumbar Interbody Fusion (LLIF)
14.6.5. Others
14.7. Middle East & Africa Spine Biologics Market Value Share Analysis, by End-User
14.8. Middle East & Africa Spine Biologics Market Forecast, by End-User
14.8.1. Hospitals
14.8.2. Ambulatory Surgical Centers
14.8.3. Others
14.9. Middle East & Africa Spine Biologics Market Value Share Analysis, by Country
14.10. Middle East & Africa Spine Biologics Market Forecast, by Country
14.10.1. GCC
14.10.2. South Africa
14.10.3. Rest of Middle East & Africa
14.11. Middle East & Africa Spine Biologics Market Analysis, by Country
14.12. GCC Spine Biologics Market Forecast, by Product
14.12.1. Bone Allografts
14.12.1.1. Machined bone allograft
14.12.1.2. Demineralized bone matrix
14.12.2. Bone Graft Substitute
14.12.2.1. Synthetic Bone Grafts
14.12.2.2. Demineralized Bone Matrix (DBM)
14.12.2.3. Bone Morphogenetic Proteins (BMP)
14.12.3. Spinal Allografts
14.12.3.1. Machined Bones Allograft
14.12.3.2. Demineralized Bone Matrix
14.12.4. Platelet Rich Plasma
14.12.5. Cell-based Matrix
14.13. GCC Spine Biologics Market Forecast, by Surgery Type
14.13.1. Anterior Cervical Discectomy and Fusion (ACDF)
14.13.2. Transforamenal Lumbar Interbody Fusion (TLIF)
14.13.3. Anterior Lumbar Interbody Fusion (ALIF)
14.13.4. Lateral Lumbar Interbody Fusion (LLIF)
14.13.5. Others
14.14. GCC Spine Biologics Market Forecast, by End-User
14.14.1. Hospitals
14.14.2. Ambulatory Surgical Centers
14.14.3. Others
14.15. South Africa Spine Biologics Market Forecast, by Product
14.15.1. Bone Allografts
14.15.1.1. Machined bone allograft
14.15.1.2. Demineralized bone matrix
14.15.2. Bone Graft Substitute
14.15.2.1. Synthetic Bone Grafts
14.15.2.2. Demineralized Bone Matrix (DBM)
14.15.2.3. Bone Morphogenetic Proteins (BMP)
14.15.3. Spinal Allografts
14.15.3.1. Machined Bones Allograft
14.15.3.2. Demineralized Bone Matrix
14.15.4. Platelet Rich Plasma
14.15.5. Cell-based Matrix
14.16. South Africa Spine Biologics Market Forecast, by Surgery Type
14.16.1. Anterior Cervical Discectomy and Fusion (ACDF)
14.16.2. Transforamenal Lumbar Interbody Fusion (TLIF)
14.16.3. Anterior Lumbar Interbody Fusion (ALIF)
14.16.4. Lateral Lumbar Interbody Fusion (LLIF)
14.16.5. Others
14.17. South Africa Spine Biologics Market Forecast, by End-User
14.17.1. Hospitals
14.17.2. Ambulatory Surgical Centers
14.17.3. Others
14.18. Rest of Middle East & Africa Spine Biologics Market Forecast, by Product
14.18.1. Bone Allografts
14.18.1.1. Machined bone allograft
14.18.1.2. Demineralized bone matrix
14.18.2. Bone Graft Substitute
14.18.2.1. Synthetic Bone Grafts
14.18.2.2. Demineralized Bone Matrix (DBM)
14.18.2.3. Bone Morphogenetic Proteins (BMP)
14.18.3. Spinal Allografts
14.18.3.1. Machined Bones Allograft
14.18.3.2. Demineralized Bone Matrix
14.18.4. Platelet Rich Plasma
14.18.5. Cell-based Matrix
14.19. Rest of Middle East & Africa Spine Biologics Market Forecast, by Surgery Type
14.19.1. Anterior Cervical Discectomy and Fusion (ACDF)
14.19.2. Transforamenal Lumbar Interbody Fusion (TLIF)
14.19.3. Anterior Lumbar Interbody Fusion (ALIF)
14.19.4. Lateral Lumbar Interbody Fusion (LLIF)
14.19.5. Others
14.20. Rest of Middle East & Africa Spine Biologics Market Forecast, by End-User
14.20.1. Hospitals
14.20.2. Ambulatory Surgical Centers
14.20.3. Others
14.21. Middle East & Africa Spine Biologics Market Attractiveness Analysis
14.21.1. By Product
14.21.2. By Surgery Type
14.21.3. By End-User
14.22. PEST Analysis
14.23. Key Trends
14.24. Key Developments

15. South America Spine Biologics Market Analysis
15.1. Key Findings
15.2. South America Spine Biologics Market Overview
15.3. South America Spine Biologics Market Value Share Analysis, by Product
15.4. South America Spine Biologics Market Forecast, by Product
15.4.1. Bone Allografts
15.4.1.1. Machined bone allograft
15.4.1.2. Demineralized bone matrix
15.4.2. Bone Graft Substitute
15.4.2.1. Synthetic Bone Grafts
15.4.2.2. Demineralized Bone Matrix (DBM)
15.4.2.3. Bone Morphogenetic Proteins (BMP)
15.4.3. Spinal Allografts
15.4.3.1. Machined Bones Allograft
15.4.3.2. Demineralized Bone Matrix
15.4.4. Platelet Rich Plasma
15.4.5. Cell-based Matrix
15.5. South America Spine Biologics Market Value Share Analysis, by Surgery Type
15.6. South America Spine Biologics Market Forecast, by Surgery Type
15.6.1. Anterior Cervical Discectomy and Fusion (ACDF)
15.6.2. Transforamenal Lumbar Interbody Fusion (TLIF)
15.6.3. Anterior Lumbar Interbody Fusion (ALIF)
15.6.4. Lateral Lumbar Interbody Fusion (LLIF)
15.6.5. Others
15.7. South America Spine Biologics Market Value Share Analysis, by End-User
15.8. South America Spine Biologics Market Forecast, by End-User
15.8.1. Hospitals
15.8.2. Ambulatory Surgical Centers
15.8.3. Others
15.9. South America Spine Biologics Market Value Share Analysis, by Country
15.10. South America Spine Biologics Market Forecast, by Country
15.10.1. Brazil
15.10.2. Mexico
15.10.3. Rest of South America
15.11. South America Spine Biologics Market Analysis, by Country
15.12. Brazil Spine Biologics Market Forecast, by Product
15.12.1. Bone Allografts
15.12.1.1. Machined bone allograft
15.12.1.2. Demineralized bone matrix
15.12.2. Bone Graft Substitute
15.12.2.1. Synthetic Bone Grafts
15.12.2.2. Demineralized Bone Matrix (DBM)
15.12.2.3. Bone Morphogenetic Proteins (BMP)
15.12.3. Spinal Allografts
15.12.3.1. Machined Bones Allograft
15.12.3.2. Demineralized Bone Matrix
15.12.4. Platelet Rich Plasma
15.12.5. Cell-based Matrix
15.13. Brazil Spine Biologics Market Forecast, by Surgery Type
15.13.1. Anterior Cervical Discectomy and Fusion (ACDF)
15.13.2. Transforamenal Lumbar Interbody Fusion (TLIF)
15.13.3. Anterior Lumbar Interbody Fusion (ALIF)
15.13.4. Lateral Lumbar Interbody Fusion (LLIF)
15.13.5. Others
15.14. Brazil Spine Biologics Market Forecast, by End-User
15.14.1. Hospitals
15.14.2. Ambulatory Surgical Centers
15.14.3. Others
15.15. Mexico Spine Biologics Market Forecast, by Product
15.15.1. Bone Allografts
15.15.1.1. Machined bone allograft
15.15.1.2. Demineralized bone matrix
15.15.2. Bone Graft Substitute
15.15.2.1. Synthetic Bone Grafts
15.15.2.2. Demineralized Bone Matrix (DBM)
15.15.2.3. Bone Morphogenetic Proteins (BMP)
15.15.3. Spinal Allografts
15.15.3.1. Machined Bones Allograft
15.15.3.2. Demineralized Bone Matrix
15.15.4. Platelet Rich Plasma
15.15.5. Cell-based Matrix
15.16. Mexico Spine Biologics Market Forecast, by Surgery Type
15.16.1. Anterior Cervical Discectomy and Fusion (ACDF)
15.16.2. Transforamenal Lumbar Interbody Fusion (TLIF)
15.16.3. Anterior Lumbar Interbody Fusion (ALIF)
15.16.4. Lateral Lumbar Interbody Fusion (LLIF)
15.16.5. Others
15.17. Mexico Spine Biologics Market Forecast, by End-User
15.17.1. Hospitals
15.17.2. Ambulatory Surgical Centers
15.17.3. Others
15.18. Rest of South America Spine Biologics Market Forecast, by Product
15.18.1. Bone Allografts
15.18.1.1. Machined bone allograft
15.18.1.2. Demineralized bone matrix
15.18.2. Bone Graft Substitute
15.18.2.1. Synthetic Bone Grafts
15.18.2.2. Demineralized Bone Matrix (DBM)
15.18.2.3. Bone Morphogenetic Proteins (BMP)
15.18.3. Spinal Allografts
15.18.3.1. Machined Bones Allograft
15.18.3.2. Demineralized Bone Matrix
15.18.4. Platelet Rich Plasma
15.18.5. Cell-based Matrix
15.19. Rest of South America Spine Biologics Market Forecast, by Surgery Type
15.19.1. Anterior Cervical Discectomy and Fusion (ACDF)
15.19.2. Transforamenal Lumbar Interbody Fusion (TLIF)
15.19.3. Anterior Lumbar Interbody Fusion (ALIF)
15.19.4. Lateral Lumbar Interbody Fusion (LLIF)
15.19.5. Others
15.20. Rest of South America Spine Biologics Market Forecast, by End-User
15.20.1. Hospitals
15.20.2. Ambulatory Surgical Centers
15.20.3. Others
15.21. South America Spine Biologics Market Attractiveness Analysis
15.21.1. By Product
15.21.2. By Surgery Type
15.21.3. By End-User
15.22. PEST Analysis
15.23. Key Trends
15.24. Key Developments

16. Company Profiles
16.1. Market Share Analysis, by Company
16.2. Competition Matrix
16.2.1. Competitive Benchmarking of key players by price, presence, market share, Applications and R&D investment
16.2.2. New Product Launches and Product Enhancements
16.2.3. Market Consolidation
16.2.3.1. M&A by Regions, Investment and Applications
16.2.3.2. M&A Key Players, Forward Integration and Backward
Integration
16.3. Company Profiles: Key Players
16.3.1. Medtronic Inc.
16.3.1.1. Company Overview
16.3.1.2. Financial Overview
16.3.1.3. Product Portfolio
16.3.1.4. Business Strategy
16.3.1.5. Recent Developments
16.3.1.6. Development Footprint
16.3.2. DePuy Synthes Companies
16.3.3. Zimmer Holding Inc.
16.3.4. Nuvasive Inc
16.3.5. Stryker Corporation
16.3.6. Orthofix International N.V.
16.3.7. Exactech Inc.
16.3.8. Wright Medical Technology
16.3.9. Alphatec Holdings
16.3.10. SeaSpine
16.3.11. Globus Medical
16.3.12. RTI Surgical

17. Primary Key Insights
  • INQUIRE BEFORE BUYING